cabiralizumab
cabiralizumab is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Clinical Trials (9)
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9